Navigation Links
MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
Date:7/9/2008

costs had more than doubled, with MDS's investment exceeding $350 million. To address these issues, MDS entered mediation with AECL that resulted in a new agreement reached in 2006. The 2006 agreement stipulated that AECL would bring the MAPLE reactors into service commencing October 2008 and provide MDS with a 40-year supply of isotopes.

On May 16, 2008, AECL and the Government of Canada announced their intention to discontinue the MAPLE project without prior notice to or consultation with MDS. AECL and the Government also made their announcements without disclosing any long-term plan for the supply of isotopes beyond extending the license of the NRU.

Prior to their announcement, in regular reviews with AECL to discuss the status of the MAPLE project, AECL had consistently maintained that it would complete the reactor project. AECL has stated that its decision will not impact current supply of medical isotopes from the NRU, and the Government has stated that it would like AECL to pursue an extension of the NRU operation beyond its current license. While MDS supports this decision, it does not adequately address long-term supply.

The Importance of Isotope Supply

Medical isotopes are used to diagnose potentially life-threatening conditions such as heart disease and to treat serious diseases such as cancer. Establishing a reliable supply of medical isotopes is an important issue for patients worldwide. The NRU is one of only four reactors in the world with the capacity to produce isotopes for commercial use. It supplies isotopes to MDS Nordion who in turn processes them into medical isotopes that are then distributed to radiopharmaceutical companies. These companies manufacture radiopharmaceuticals and distribute them to hospitals and radiopharmacies around the world.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the de
'/>"/>

SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
2. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
3. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
4. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
5. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
6. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. Cytopia Commences Phase II Cancer Drug Study
9. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
10. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
11. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 2Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 3Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 2Health News:Study Suggests Need for More Aggressive Outpatient Monitoring of Patients' Hearts When Cause of Stroke is Unclear 3Health News:Zimbabwean Health Workers Call For Crisis Response 2Health News:Zimbabwean Health Workers Call For Crisis Response 3Health News:Bloomberg School awards Goodermote Humanitarian Award to Soledad O'Brien 2Health News:Interim HealthCare Recognizes Outstanding Franchisees at National Clinical Symposium 2Health News:Interim HealthCare Recognizes Outstanding Franchisees at National Clinical Symposium 3Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 2Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 3
Breaking Medicine Technology:Vivakor Announces New Acquisition Strategy 2Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility 2Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 1PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 1Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 2Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 4Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 5Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 6Sorafenib significantly improves the length of time before breast cancer worsens 58117 1Sorafenib significantly improves the length of time before breast cancer worsens 58117 2